Olaratumab Exerts Antitumor Activity in Preclinical Models of Pediatric Bone and Soft Tissue Tumors through Inhibition of Platelet-Derived Growth Factor Receptor α.
Lowery, Caitlin D
Olaratumab Exerts Antitumor Activity in Preclinical Models of Pediatric Bone and Soft Tissue Tumors through Inhibition of Platelet-Derived Growth Factor Receptor α. [electronic resource] - Clinical cancer research : an official journal of the American Association for Cancer Research 02 2018 - 847-857 p. digital
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
1557-3265
10.1158/1078-0432.CCR-17-1258 doi
Animals
Antibodies, Monoclonal--administration & dosage
Antineoplastic Combined Chemotherapy Protocols--pharmacology
Cell Line
Cell Line, Tumor
Child
Disease-Free Survival
Humans
Mice, Nude
Receptor, Platelet-Derived Growth Factor alpha--antagonists & inhibitors
Sarcoma--drug therapy
Soft Tissue Neoplasms--drug therapy
Tumor Burden--drug effects
Xenograft Model Antitumor Assays
Olaratumab Exerts Antitumor Activity in Preclinical Models of Pediatric Bone and Soft Tissue Tumors through Inhibition of Platelet-Derived Growth Factor Receptor α. [electronic resource] - Clinical cancer research : an official journal of the American Association for Cancer Research 02 2018 - 847-857 p. digital
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
1557-3265
10.1158/1078-0432.CCR-17-1258 doi
Animals
Antibodies, Monoclonal--administration & dosage
Antineoplastic Combined Chemotherapy Protocols--pharmacology
Cell Line
Cell Line, Tumor
Child
Disease-Free Survival
Humans
Mice, Nude
Receptor, Platelet-Derived Growth Factor alpha--antagonists & inhibitors
Sarcoma--drug therapy
Soft Tissue Neoplasms--drug therapy
Tumor Burden--drug effects
Xenograft Model Antitumor Assays